The United States is expected to adopt international pricing benchmarks as a standard practice for determining drug prices by 2026. This approach, often referred to as “Most Favored Nation” (MFN) pricing, ties U.S. drug costs to the prices paid in other countries. Once considered an unlikely policy shift, this method has gained traction in recent years and is anticipated to play a central role in shaping the nation’s pharmaceutical pricing strategies moving forward.
The MFN model links the cost of medications in the U.S. to lower prices established in foreign markets, aiming to address concerns over high domestic drug costs. This development reflects growing bipartisan support for reforms targeting affordability and accessibility within the healthcare system. The move signals a significant departure from traditional market-driven pricing mechanisms that have long dominated the U.S. pharmaceutical industry. Observers note that this shift aligns with broader global trends and increasing pressure on policymakers to implement cost-containment measures while ensuring equitable access to essential medicines.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: January 15, 2026
發佈留言